Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  idarubicin hydrochloride
Find trials that include:  Any drugs shown
Results 1-25 of 28 for your search:
Start Over
Tretinoin and Arsenic Trioxide in Treating Patients with Untreated Acute Promyelocytic Leukemia
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 to 21
Trial IDs: AAML1331, NCI-2014-02266, PAAML1331_A01PAMDREVW0, NCT02339740
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 2215-CL-0301, NCI-2015-00931, 2015-000140-42, NCT02421939
Quizartinib With Standard of Care Chemotherapy and as Maintenance Therapy in Patients With Newly Diagnosed FLT3-ITD (+) AML
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 to 75
Trial IDs: AC220-A-U302, NCI-2016-00846, NCT02668653
Clofarabine or Fludarabine Phosphate in Combination with Idarubicin and Cytarabine in Treating Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2010-0788, NCI-2011-00251, NCT01289457
Combination Chemotherapy in Treating Patients with Recurrent Acute Myeloid Leukemia or Recurrent Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 64
Trial IDs: 2012-1064, NCI-2013-00548, NCT01794702
Dasatinib, Cytarabine, and Idarubicin Hydrochloride in Treating Patients with High-Risk Acute Myeloid Leukemia
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: 12393, NCI-2013-01141, 106482, NCT01876953
Chemotherapy and Donor Lymphocytes in Treating Older Patients with High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 55 and over
Trial IDs: Pro00043247, NCI-2014-00663, NCT02046122
Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GMI-1271-201, NCI-2015-01237, NCT02306291
Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ARO-010, NCI-2015-01403, NCT02400281
Idarubicin, Cytarabine, and Nivolumab in Treating Patients with High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0907, NCI-2015-01258, NCT02464657
Nintedanib, Idarubicin Hydrochloride, and Cytarabine in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 1507016193, NCI-2016-00754, NCT02665143
A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: NLG2106, NCI-2016-01685, NCT02835729
Idarubicin, Cytarabine, and Pravastatin in Treating Patients with Poor-Risk Acute Myeloid Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: S0919, NCI-2009-01183, CDR0000633749, SWOG-S0919, NCT00840177
Chemotherapy in Treating Patients with Myelodysplastic Syndrome before Donor Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 2661.00, NCI-2013-00538, 2661, NCT01812252
DNA Methyltransferase Inhibitor SGI-110 with or without Idarubicin or Cladribine in Treating Older Patients with Previously Untreated Acute Myeloid Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: Over 70
Trial IDs: 2013-0843, NCI-2014-00981, NCT02096055
Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients with Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 65
Trial IDs: 2013-0073, NCI-2014-02322, NCT02135874
A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ARO-006, NCI-2015-00952, NCT02283177
Alisertib in Combination with Cytarabine and Idarubicin in Treating Patients with High-Risk Acute Myeloid Leukemia
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-334, NCI-2016-00332, NCT02560025
Randomized Study of CX-01 Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 60 and over
Trial IDs: CNTX-CX-01-2015-AML-1, NCI-2016-01309, NCT02873338
A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2215-CL-0103, NCI-2014-01987, NCT02236013
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AG120-221-C-001, NCI-2015-02291, NCT02632708
CXCR4 Peptide Antagonist LY2510924, Idarubicin and Cytarabine in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: 2015-0436, NCI-2016-00259, NCT02652871
Ibrutinib, Idarubicin and Cytarabine in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: HEMAML0036, NCI-2015-01961, 35003, IRB-35003, NCT02635074
Dasatinib in Combination with Chemotherapy in Treating Younger Patients with Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: AFLACLL1401, NCI-2015-01013, IRB00078620, NCT02680951
Start Over